| Drug Discovery for Parkinson's With Mutations in the GBA Gene (NCT05536388) | New York Stem Cell Foundation Research Institute | 2022-07-15 |
| Digital Health Platform Customized for Patients With Gaucher Disease (NCT04997772) | Shoshana Vilk | 2022-02-01 |
| Post Marketing Surveillance (PMS) Study for Velaglucerase Alfa (VPRIV) in India (NCT04429984) | Shire | 2021-07-28 |
| ScreenPlus: A Comprehensive, Flexible, Multi-disorder Newborn Screening Program (NCT05368038) | Albert Einstein College of Medicine | 2021-05-10 |
| A Study of Enzyme Replacement Therapy (VPRIV) in People With Type 1 Gaucher Disease Who Were Previously Treated With Substrate Reduction Therapy (NCT04718779) | Takeda | 2021-04-22 |
| A Study of Velaglucerase Alfa (VPRIV) Given as Standard Patient Care in Young Children With Gaucher Disease (NCT04721366) | Takeda | 2021-01-08 |
| Complement Activation in the Lysosomal Storage Disorders (NCT04189601) | Melbourne Health | 2020-09-30 |
| Getting Global Rare Disease Insights Through Technology Study (NCT04758130) | M.A.G.I.C. Clinic LTD | 2020-08-07 |
| World Data on Ambroxol for Patients With GD and GBA Related PD (NCT04388969) | Shaare Zedek Medical Center | 2020-05-06 |
| A Phase I Study to Compare Abcertin and EU-sourced Cerezyme® in Healthy Volunteers (NCT04787887) | ISU Abxis Co., Ltd. | 2020-01-29 |
| A Study of VPRIV in Participants With Gaucher Disease Previously Treated With Other Enzyme Replacement Therapies or Substrate Reduction Therapies (NCT04094181) | Shire | 2019-09-19 |
| Lentiviral Vector Gene Therapy - The Guard1 Trial of AVR-RD-02 for Subjects With Type 1 Gaucher Disease (NCT04145037) | AVROBIO | 2019-05-30 |
| Therapeutic Exercise to Treat Neuropathic Pain (NCT04050137) | Universidad de Zaragoza | 2019-05-02 |
| The GBA Multimodal Study in Parkinson's Disease (NCT04101968) | Pacific Parkinson's Research Centre | 2019-05-01 |
| Liver and the Spleen Stifness in Adult Patients With Gaucher's Disease Using Ultrasound Shear Wave Elastography (NCT03896607) | HaEmek Medical Center, Israel | 2019-03-30 |
| Lyso-Gb1 as a Long-term Prognostic Biomarker in Gaucher Disease (NCT02416661) | CENTOGENE GmbH Rostock | 2018-08-27 |
| Clinical Audit of Managment of Gausher Disease in Children (NCT03590548) | Yasmeen Abd Elbaset Hamzaa | 2018-07-01 |
| Chronic Hepatitis C Treatment in Egyptian Children With Gaucher Disease. (NCT03721627) | Mansoura University Children Hospital | 2018-04-03 |
| Biomarker Analysis for GBA Associated Parkinson's Disease (NCT03811496) | Lysosomal and Rare Disorders Research and Treatment Center, Inc. | 2018-02-01 |
| A Long-term Follow-up Study of Gaucher Disease (NCT03190837) | Duke University | 2017-06-12 |
| Study of the Effect of Velaglucerase Alfa (VPRIV®) on Bone-related Pathology in Treatment-naïve Participants With Type 1 Gaucher Disease (NCT02574286) | Shire | 2016-06-29 |
| Genzyme Osteopenia/Osteoporosis Study (NCT02785744) | NYU Langone Health | 2016-04-01 |
| Phase 3b Study to Evaluate Skeletal Response to Eliglustat in Adult Patients Who Completed Phase 2 or Phase 3 Studies (NCT02536755) | Genzyme, a Sanofi Company | 2015-10-27 |
| A National Study in Patients With Unexplained Splenomegaly (NCT04430881) | Sanofi | 2015-09-01 |
| A Study of the Effects of Renal Impairment on the Pharmacokinetics and Tolerability of Eliglustat Tartrate (NCT02536937) | Sanofi | 2015-09-01 |
| A Study of the Effects of Hepatic Impairment on the Pharmacokinetics and Tolerability of Eliglustat Tartrate (NCT02536911) | Genzyme, a Sanofi Company | 2015-09-01 |
| Miglustat on Gaucher Disease Type IIIB (NCT02520934) | National Taiwan University Hospital | 2015-07-01 |
| SRT in Comparison to ERT on Immune Aspects and Bone Involvement in Gaucher Disease (NCT02605603) | Lysosomal and Rare Disorders Research and Treatment Center, Inc. | 2015-05-01 |
| Taste Evaluation of Different Liquid Formulations With Eliglustat (NCT02422654) | Genzyme, a Sanofi Company | 2015-04-01 |
| Survey Study for Velaglucerase Alfa (VPRIV) in Japan (NCT03625882) | Takeda | 2014-09-02 |
| An Open-Label, Dose Escalation Study to Evaluate the Safety and the Pharmacokinetics of Oral PRX-112 (NCT02107846) | Protalix | 2014-04-01 |
| Investigating Lysosomal Storage Diseases in Minority Groups (NCT02120235) | O & O Alpan LLC | 2014-02-01 |
| Multicenter Extension Study of Velaglucerase Alfa in Japanese Patients With Gaucher Disease (NCT01842841) | Shire | 2013-03-13 |
| Safety and Pharmacokinetics of Oral PRX-112 in Gaucher Disease Patients (NCT01747980) | Protalix | 2013-03-01 |
| Intra-monocyte Imiglucerase Kinetics in Gaucher Disease (NCT01951989) | University Hospital, Clermont-Ferrand | 2012-11-01 |
| Identification of Undiagnosed Gaucher Disease (NCT01716741) | Brigham and Women's Hospital | 2012-08-01 |
| Longitudinal Study of Neurodegenerative Disorders (NCT03333200) | University of Pittsburgh | 2012-01-11 |
| Clinical and Pathophysiological Investigations Into Erdheim Chester Disease (NCT01417520) | National Human Genome Research Institute (NHGRI) | 2011-08-01 |
| A Multicenter Extension Study of Taliglucerase Alfa in Adult Subjects With Gaucher Disease (NCT01422187) | Pfizer | 2011-08-01 |
| Detecting Dopaminergic Deficits in Individuals At-risk for Parkinsonism (NCT01358474) | University of Minnesota | 2011-07-01 |
| A Switch-Over Study of the Safety and Efficacy of ISU302 in Patients With Type 1 Gaucher Disease (NCT02053896) | ISU Abxis Co., Ltd. | 2011-05-01 |
| Exploration of Immunity in Gaucher Disease (NCT01358188) | O & O Alpan LLC | 2011-04-01 |
| Examining the Immune Response in Patients With Gaucher Disease and Hepatitis C (NCT01274208) | Shaare Zedek Medical Center | 2011-01-01 |
| Gaucher Disease Outcome Survey (GOS) (NCT03291223) | Shire | 2010-12-29 |
| Thrombocytopathy in Gaucher Disease Patients (NCT01344096) | Rabin Medical Center | 2010-10-01 |
| A Study of the Tolerability, Safety, and Pharmacokinetics of ISU302 in Healthy Volunteers (NCT01881633) | ISU Abxis Co., Ltd. | 2010-10-01 |
| A Safety and Efficacy Study of Two Dose Levels of Taliglucerase Alfa in Pediatric Subjects With Gaucher Disease (NCT01132690) | Pfizer | 2010-08-01 |
| A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease to Evaluate Once Daily Versus Twice Daily Dosing (EDGE) (NCT01074944) | Genzyme, a Sanofi Company | 2010-06-01 |
| Validating a New Severity Score System for Adults With Type 1 Gaucher Disease (GD1) (NCT01136304) | University Research Foundation for Lysosomal Storage Diseases, Inc. | 2010-04-01 |
| Auto-antibodies Prevalence and CD1 Role in Gaucher Disease (NCT02650219) | Hospital St. Joseph, Marseille, France | 2010-01-01 |
| Cellular and Molecular Mechanisms Governing Bone Marrow Stem Cells in Gaucher Disease (NCT01439607) | Assistance Publique - Hôpitaux de Paris | 2009-12-01 |
| A Long-Term Extension Study of AT2101 (Afegostat Tartrate) in Type 1 Gaucher Patients (NCT00813865) | Amicus Therapeutics | 2009-05-11 |
| Switchover Trial From Imiglucerase to Plant Cell Expressed Recombinant Human Glucocerebrosidase (NCT00712348) | Pfizer | 2008-12-01 |
| A Study of Oral AT2101 (Afegostat Tartrate) in Treatment-naive Patients With Gaucher Disease (NCT00446550) | Amicus Therapeutics | 2008-06-11 |
| Plant Cell Expressed Recombinant Human Glucocerebrosidase Extension Trial (NCT00705939) | Pfizer | 2008-06-01 |
| A Phase III Trial to Assess the Safety and Efficacy of Plant Cell Expressed GCD in Patients With Gaucher Disease (NCT00376168) | Pfizer | 2007-08-01 |
| Study of GA-GCB Enzyme Replacement Therapy in Type 1 Gaucher Disease Patients Previously Treated With Imiglucerase (NCT00478647) | Shire | 2007-07-25 |
| A Study to Evaluate and Characterize the Effect of Pharmacological Chemicals on Blood From Patients With Gaucher Disease (NCT00465062) | National Institute of Neurological Disorders and Stroke (NINDS) | 2007-04-19 |
| A Study of AT2101 (Afegostat Tartrate) in Adult Patients With Type 1 Gaucher Disease Currently Receiving Enzyme Replacement Therapy (NCT00433147) | Amicus Therapeutics | 2007-03-23 |
| Study to Evaluate Blood Cell Lines From Patients With Gaucher Disease (NCT00351156) | Amicus Therapeutics | 2006-07-01 |
| Positron Emission Tomography (PET) Imaging in People With Gaucher Mutations (NCT00302146) | National Human Genome Research Institute (NHGRI) | 2006-05-23 |
| Open-Label Extension Study Evaluating Long Term Safety in Patients With Type 1 Gaucher Disease Receiving DRX008A (ERT) (NCT00391625) | Shire | 2004-09-13 |
| OGT 918-006: A Phase I/II Randomized, Controlled Study of OGT 918 in Patients With Neuronopathic Gaucher Disease (NCT00041535) | National Institute of Neurological Disorders and Stroke (NINDS) | 2002-07-05 |
| Genetic Studies of Lysosomal Storage Disorders (NCT00001215) | National Human Genome Research Institute (NHGRI) | 1995-03-08 |
| International Collaborative Gaucher Group (ICGG) Gaucher Disease Registry & Pregnancy Sub-registry (NCT00358943) | Genzyme, a Sanofi Company | 1991-04-01 |
| Expanded Access Trial of Plant Expressed Recombinant Glucocerebrosidase (prGCD) in Patients With Gaucher Disease (NCT00962260) | Pfizer | |